Among the 76 basal-like triple-negative FMCs, 18% (14/76) were Bcl-2–positive, and were associated with a better outcome in terms of overall survival, and specific survival, independently of the pathologic nodal stage or the WHO cancer stage. This evidence concerns the gene BCL2 and cancer.